Substituted piperazines
US7842693B2 · kind B2 · utility
10Cited by
53References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2003 |
| Grant date | Nov 30, 2010 |
| Priority date | — |
| Expiry date | Jan 2, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/34
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Compounds are provided that act as potent antagonists of the CCR1 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR1. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.